Rotem Petranker
Psychedelic researcher; doctoral candidate in Psychology, Brain, and Behaviour at McMaster University
Data updated
Research Footprint
Rotem Petranker appears in 5 tracked papers (2019–2024), most studied alongside Psilocybin and LSD, across Microdosing, Anxiety Disorders and Substance Use Disorders (SUD).
Most-cited paper: Microdosing psychedelics: personality, mental health, and creativity differences in microdosers (169 citations).
Frequent co-authors: Cory Ross Weissman, Philippe Lucas and Muhammad Ishrat Husain.
Background & Research
Rotem Petranker earned a BSc in psychology from the University of Toronto, an MA in social psychology from York University, and a PhD from McMaster University. His research has focused on psychedelic microdosing, including observational studies, qualitative analyses, and a recent double-blind randomized controlled trial on psilocybin microdosing. He has also been associated with the University of Toronto Mississauga’s Psychedelics Studies Research program and has founded/led related psychedelic science initiatives.
Key Impact
He is a leading microdosing researcher whose work has helped define the demographics, practices, benefits, and challenges of psychedelic microdosing.
Collaboration Network
3 collaborators· click a node to visit their profile
Full network →Affiliations
Institutions, companies, and organisations Rotem Petranker is associated with.
McMaster University
A Canadian research university in Hamilton, Ontario, McMaster University houses the Centre for Medicinal Cannabis Research and an expanding psychedelic science program including the McMaster Psychedelic Research Society; the university is sponsoring the PSI_CUD trial—a Phase 2 proof-of-concept study of psilocybin-assisted psychotherapy (two 25mg doses within an 8-week Motivational Enhancement Therapy framework) for cannabis use disorder.
View stakeholder →University of Toronto Mississauga
academicThe Psychedelic Studies Research Program (PSRP) distinguishes itself by adhering strictly to the principles of Open Science, pre-registering their analysis plans, and making their data and protocols freely accessible. A primary focus for the team at the PSRP is the clinical study of microdosing. Led by Dr. Norman Farb, the program conducts double-blind, randomized controlled trials investigating the benefits and drawbacks of microdosing very low doses of psilocybin.
View stakeholder →